Which countries have the highest breast cancer rates? (as of 2026)

The source material does not include country-by-country breast cancer incidence rankings; it only covers survival and diagnosis trends for Korea and the United States. One notable feature of Korea is that breast cancer tends to be diagnosed at a younger age than in Western countries.

Key Takeaways

• Korea's 5-year relative survival rate for breast cancer is 94.7% (National Cancer Registration Statistics 2019–2023, Central Cancer Registry, National Cancer Center Korea).
• The 5-year relative survival rate for women's breast cancer from the U.S. SEER data is 91.9% (SEER 2016–2022).
• Both figures are nationwide statistics, not the results of any particular hospital, and they are not numbers that indicate an international ranking of incidence rates.
• Breast cancer in Korea tends to be diagnosed at a younger age compared to Western countries, which has led to well-developed care pathways that address breast conservation, reconstruction, and fertility preservation together.
• Korea offers a national mammography screening program every two years starting at age 40, and about 30,000 cases were diagnosed in a single year, 2023 (National Cancer Registration Statistics).
• Survival rates and case counts are population-level averages and are not numbers that predict any individual's outcome.

Can I find out the country ranking for breast cancer incidence?

• The provided material does not include rankings or comparative statistics by country, so this note alone cannot answer which country has the most breast cancer cases.
• However, according to Korean domestic statistics, about 30,000 new cases of breast cancer were diagnosed in 2023 alone (National Cancer Registration Statistics), and breast cancer is not treated as a single disease — it is classified into several subtypes, each with a different course and treatment approach.
• Therefore, rather than 'which country has more cases,' the subtype and stage an individual belongs to is treated as far more important information for treatment and prognosis.

How do breast cancer survival rates differ between Korea and the U.S.?

• Korea's 5-year relative survival rate is 94.7% (National Cancer Registration Statistics 2019–2023), while the U.S. SEER figure is 91.9% (2016–2022); both figures represent nationwide average statistics.
• This difference is understood to arise not simply from differences in treatment technology, but from a mix of factors including screening systems, the stage distribution at diagnosis, and population composition — it is not a number that represents the performance of any particular hospital.
• Because survival rates are population averages, they do not predict an individual's outcome; actual prognosis varies greatly depending on subtype — such as hormone receptor and HER2 status — and stage.

Why is breast cancer said to occur more often at a younger age in Korea?

• According to the material, there is a confirmed trend in Korea toward breast cancer being diagnosed at a younger age at a higher rate compared to Western countries.
• Because of this trend, a care pathway has naturally developed that includes counseling together on breast-conserving surgery, reconstruction, and preserving the ability to become pregnant and fertility after treatment.
• Before starting chemotherapy, patients can receive counseling on freezing eggs or embryos, and since preparation takes time, it is common to schedule this in advance during the early review stage.

FAQ — Is breast cancer a single disease?

No. Breast cancer is an umbrella term for a group of cancers that are divided into several subtypes based on hormone receptor status (ER, PR), HER2 status, and the Ki-67 test, which measures how fast cells are proliferating. Because the surgical sequence and medications used differ completely depending on the subtype, an individual's subtype and stage serve as a far more important criterion for determining the direction of treatment than an overall survival rate figure.

FAQ — Are the survival rates cited here the results of a specific hospital?

No. The 94.7% figure (Korea, National Cancer Registration Statistics 2019–2023) and the 91.9% figure (U.S., SEER 2016–2022) cited in this article are both nationwide statistics covering the entire country, not the treatment outcomes of any individual hospital. Under Korea's Medical Service Act, hospitals are not permitted to use hospital-specific outcome figures in advertising, and actual results vary greatly from person to person depending on subtype and stage.

Sources and Notes

• This article was written based on National Cancer Registration Statistics 2019–2023 (Central Cancer Registry, National Cancer Center Korea) and SEER 2016–2022 (U.S. National Cancer Institute).
• This content is intended for general medical information purposes only, and diagnosis, treatment methods, and outcomes may vary depending on an individual's condition. Please be sure to consult with a medical professional to determine an accurate diagnosis and treatment plan.